Lenalidomid Ratiopharm (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the degradation of transcription factors Ikaros and Aiolos, which in turn produces anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects against malignant blood cells.

The specific dose of Lenalidomid Ratiopharm is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to set the appropriate regimen.

Lenalidomid Ratiopharm is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or other agents and provides benefits in progression‑free survival, especially in patients who have relapsed after prior therapies.

Store Lenalidomid Ratiopharm at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid storing it in areas with high humidity or temperature fluctuations.

Lenalidomid Ratiopharm is taken orally, usually with a glass of water. The exact timing (e.g., with or without food) and dosing schedule are determined by the prescribing physician and should follow the instructions on the prescription label.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe cutaneous reactions like Stevens‑Johnson syndrome, and the potential development of secondary malignancies such as acute myeloid leukemia. Patients should be monitored closely for these events.

Lenalidomid Ratiopharm should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments are made. It is also contraindicated in patients who cannot comply with required contraception measures.